

A210 JACC April 1, 2014 Volume 63, Issue 12



PROVIDER VARIABILITY AND CHARACTERISTICS ASSOCIATED WITH BIVALIRUDIN USE FOR BLEEDING AVOIDANCE IN PERCUTANEOUS CORONARY INTERVENTION AFTER IMPLEMENTATION OF A DECISION SUPPORT TOOL

Poster Contributions Hall C Sunday, March 30, 2014, 3:45 p.m.-4:30 p.m.

Session Title: Acute Coronary Syndromes: Treatment Considerations Abstract Category: 1. Acute Coronary Syndromes: Clinical Presentation Number: 1226-250


Authors: <u>Timothy J. Fendler</u>, Philip Jones, Henry Ting, Faraz Kureshi, Adam Salisbury, Praneet Sharma, Adnan Chhatriwalla, John Spertus, Saint Luke's Mid America Heart Institute, Kansas City, MO, USA, Mayo Clinic, Rochester, MN, USA

Background: A decision support tool (DST) should theoretically help physicians deliver evidence-based, patient-centered care. We examined physicians' changes in bivalirudin use after provision of patient-specific bleeding risk estimates at time of PCI.

Methods: In a 9-center study of 9,383 propensity-matched patients treated by 145 physicians, we used hierarchical models to estimate physicians' changes in bivalirudin use, both overall and as a function of bleeding risk, adjusting for center and pre-DST bivalirudin use. We then examined physician characteristics (age, sex, country of schooling, interventional cardiology (IC) certification and number of publications) associated with change in bivalirudin use.

Results: After DST provision, physicians varied significantly on overall bivalirudin use (OR range 0.21-9.34; p 0.006) and use per 1% higher bleeding risk (OR range 0.34-1.78; p 0.02) (figure). In adjusted analyses, older age (OR 1.46; Cl 1.1-1.95) and IC certification (OR 3.23; Cl 1.41-7.37) were associated with increased overall bivalirudin use, while IC certification was paradoxically associated with decreased bivalirudin use in patients at higher bleeding risk (OR 0.58; Cl 0.35-0.95).

Conclusion: We observed marked variability in how physicians used bivalirudin in response to a DST. This highlights an opportunity to improve rational bivalirudin use by further exploring physician barriers to DSTs as a means of supporting safer, more effective care.



Odds Ratio for Overall Bivalirudin Use